2:05 AM
 | 
Jul 16, 2019
 |  BioCentury  |  Finance

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

How AM-Pharma turned to European venture investors to fund a Phase III study of recAP to treat acute kidney injury

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury.

CEO Erik van den Berg told BioCentury that the all-European syndicate came together quickly, with first-time investors LSP and Andera Partners leading the round. “Investments close to home are relatively easier to conduct,” he said, although he added that the company is open to working with U.S.-based...

Read the full 416 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >